Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) – Research analysts at Leerink Swann decreased their FY2017 earnings per share estimates for shares of Sucampo Pharmaceuticals in a note issued to investors on Friday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings per share of $1.02 for the year, down from their prior estimate of $1.04. Leerink Swann currently has a “Outperform” rating and a $15.00 target price on the stock. Leerink Swann also issued estimates for Sucampo Pharmaceuticals’ FY2020 earnings at $1.81 EPS and FY2021 earnings at $1.93 EPS.

SCMP has been the topic of several other reports. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Tuesday, October 17th. UBS AG decreased their price objective on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, October 12th. Roth Capital set a $30.00 price objective on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Maxim Group reiterated a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of Sucampo Pharmaceuticals in a report on Tuesday, August 8th. Finally, TheStreet downgraded shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $16.50.

TRADEMARK VIOLATION NOTICE: “Leerink Swann Comments on Sucampo Pharmaceuticals, Inc.’s FY2017 Earnings (SCMP)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/11/06/leerink-swann-comments-on-sucampo-pharmaceuticals-inc-s-fy2017-earnings-scmp.html.

Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at $10.70 on Monday. Sucampo Pharmaceuticals has a fifty-two week low of $9.30 and a fifty-two week high of $17.55. The company has a market cap of $495.52, a price-to-earnings ratio of 7.23, a price-to-earnings-growth ratio of 3.27 and a beta of 1.38. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The firm had revenue of $61.27 million for the quarter, compared to the consensus estimate of $58.05 million. During the same period in the previous year, the company earned $0.30 earnings per share. The company’s quarterly revenue was up 5.9% on a year-over-year basis.

In related news, major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jason Patrick Meyenburg purchased 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The stock was acquired at an average price of $12.13 per share, for a total transaction of $48,520.00. Following the completion of the purchase, the insider now directly owns 30,228 shares of the company’s stock, valued at approximately $366,665.64. The disclosure for this purchase can be found here. Corporate insiders own 4.13% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. HPM Partners LLC acquired a new position in shares of Sucampo Pharmaceuticals in the second quarter valued at about $1,307,000. Louisiana State Employees Retirement System grew its stake in shares of Sucampo Pharmaceuticals by 1.0% in the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 100 shares in the last quarter. Karp Capital Management Corp acquired a new position in shares of Sucampo Pharmaceuticals in the first quarter valued at about $119,000. Nine Chapters Capital Management LLC bought a new stake in Sucampo Pharmaceuticals during the third quarter worth about $127,000. Finally, First Citizens Bank & Trust Co. bought a new stake in Sucampo Pharmaceuticals during the second quarter worth about $116,000. Institutional investors and hedge funds own 55.76% of the company’s stock.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.